Fate Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Fate Therapeutics sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).
Fate Therapeutics: 22 sponsored US clinical trials, 3 recruiting.
Fate Therapeutics sponsors 22 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Precursor B-Cell Acute Lymphoblastic Leukemia, with 1 trials.
Top-decile sponsor footprint
Fate Therapeutics ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
7 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (38.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
22 total, page 1 of 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
NCT06308978
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
NCT06241456
FT819 in Subjects With B-cell Malignancies
NCT04629729
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
NCT05950334
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NCT05395052
FT576 in Subjects With Multiple Myeloma
NCT05182073
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NCT05069935
FT538 in Subjects With Advanced Hematologic Malignancies
NCT04614636
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NCT04551885
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
NCT04245722
FT516 in Subjects With Advanced Hematologic Malignancies
NCT04023071
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
NCT04093622
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
NCT04106167
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
NCT03841110
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
NCT03319459
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
NCT02743351
A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders
NCT02354443
A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies
NCT02354417
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
NCT01627314
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
NCT01527838
Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.
NCT00890500
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Fate Therapeutics pipeline
3 recruiting of 22 indexed (14% open); 7 completed (32%).
Phase mix: 0 late (III/IV) vs 20 early (I/II) (early-phase heavy).
Top condition: Precursor B-Cell Acute Lymphoblastic Leukemia (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fate Therapeutics: open-pipeline peers nationwide
Peers matched on 22 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Fate Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 22 trials (± recruiting share)
- Alaunos Therapeutics · 22 trials · 0% recruiting
- Alexza Pharmaceuticals · 22 trials · 0% recruiting
- Calithera Biosciences · 22 trials · 0% recruiting
- Griffin Hospital · 22 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- InMode MD · 14% recruiting · 22 trials
- Rigel Pharmaceuticals · 14% recruiting · 22 trials
- Reproductive Medicine Associates of New Jersey · 14% recruiting · 51 trials
- Beth Israel Deaconess Medical Center · 14% recruiting · 488 trials
Related
What to do with this Fate Therapeutics page
22 registered trials is a research-attention snapshot, not an endorsement of Fate Therapeutics or any single study.
- 3 of Fate Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Precursor B-Cell Acute Lymphoblastic Leukemia is the condition Fate Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Precursor B-Cell Acute Lymphoblastic Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Fate Therapeutics pipeline card: 22 registered trials from official public datasets.Report a data error.